Results 321 to 330 of about 324,464 (367)

Inter‐atrial block as a predictor of adverse outcomes in patients with HFpEF

ESC Heart Failure, Volume 12, Issue 3, Page 2287-2297, June 2025.
Abstract Aims Inter‐atrial block (IAB), a marker of electrical atrial dysfunction, is associated with an increased risk of atrial fibrillation (AF) and adverse events in various populations. The prognostic impact of IAB in heart failure (HF) with preserved ejection fraction (HFpEF) remains unknown.
Jerremy Weerts, Sanne G.J. Mourmans, Helena Lopez‐Martinez, Mar Domingo, Arantxa Barandiarán Aizpurua, Michiel T.H.M. Henkens, Anouk Achten, Josep Lupón, Hans‐Peter Brunner‐La Rocca, Christian Knackstedt, Antoni Bayés‐Genís, Vanessa P.M. van Empel   +11 more
wiley   +1 more source

Expanding the Role of Heparin Derivatives in Oncology: From Anticoagulation to Antitumor Activity. [PDF]

Pharmaceuticals (Basel)
Holail J, Sukkarieh HH, Aljada A.
europepmc   +1 more source

Long‐term outcomes of apixaban as main anticoagulant in patients with HeartMate 3 left ventricular assist devices

ESC Heart Failure, Volume 12, Issue 3, Page 1714-1718, June 2025.
Abstract Aims HeartMate 3 (HM3) left ventricular assist devices (LVADs) offer improved haemocompatibility‐related outcomes for end‐stage heart failure patients, facilitating the exploration of alternative anticoagulation therapies beyond warfarin.
Jennifer Jdaidani, Mahmoud Shadi, Nnedi Asogwa, Jennifer Winik, Dora Rossi, Christina Saikus, Maria D. Avila, Geurys R. Rojas‐Marte   +7 more
wiley   +1 more source

Update on the Laboratory Diagnosis of Lupus Anticoagulant: Current Challenges and Clinical Involvement. [PDF]

J Clin Med
Marco-Rico A.
europepmc   +1 more source

Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE‐HF and PRESERVED‐HF

ESC Heart Failure, Volume 12, Issue 3, Page 1676-1681, June 2025.
Abstract Aims Sodium–glucose co‐transporter‐2 (SGLT2) inhibitors improve health status and outcomes in the setting of heart failure (HF) across the range of ejection fraction (EF). Baseline kidney disease is common in HF, complicates HF management and is strongly linked to worse health status. This study aimed to assess whether the treatment effects of
Andrew P. Ambrosy, Andrew J. Sauer, Shachi Patel, Sheryl L. Windsor, Barry A. Borlaug, Mansoor Husain, Silvio E. Inzucchi, Dalane W. Kitzman, Darren K. McGuire, Sanjiv J. Shah, Kavita Sharma, Guillermo Umpierrez, Mikhail N. Kosiborod   +12 more
wiley   +1 more source

Factors influencing medication adherence for deep vein thrombosis prevention in post-discharge patients after joint replacement surgery: a qualitative study based on Protection Motivation Theory. [PDF]

BMJ Open
Fu F, Jiang J, Gu W, Li L, Zhang J, Deng X, Liu C, Tian L, Li Y.   +8 more
europepmc   +1 more source

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai, Hirohiko Aikawa, Yoshiaki Morita, Keiko Ohta‐Ogo, Teruo Noguchi   +4 more
wiley   +1 more source

Facilitating active participation in anticoagulant decisions in advanced kidney disease: co-production of a question prompt list. [PDF]

BMC Nephrol
Parker K, Needham A, Thachil J, Mitra S, Lewis P.   +4 more
europepmc   +1 more source

Left atrial appendage occlusion: behind the bleeding risk. [PDF]

Eur Heart J Suppl
Lorenzoni G, Merella P, Casu G.
europepmc   +1 more source

Enhancing Safety in Regional Anesthesia: Guidelines from the Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI). [PDF]

J Anesth Analg Crit Care
Torrano V, Anastasi S, Balzani E, Barbara E, Behr AU, Bosco M, Buttarelli C, Bruletti S, Bugada D, Cadeddu C, Cappelleri G, Cardia L, Casarano S, Cortegiani A, D'Ambrosio F, Del Vicario M, Fanelli A, Fusco P, Gazzerro G, Ghisi D, Giarratano A, Gori F, Greco M, Grossi PA, Manassero A, Russo G, Sardo S, Savoia C, Tescione M, Tinti G, De Cassai A.   +30 more
europepmc   +1 more source